Cesca Therapeutics Inc. (NASDAQ:KOOL) Q2 2019 Earnings Conference Call - Final Transcript
Aug 13, 2019 • 04:30 pm ET
cash equivalents totaling $2.4 million compared with approximately the same number at December 31, 2018.
Finally, I'd like to conclude with the most significant financial information. As Chris previously discussed, the company was adjusted EBITDA positive for the second quarter of 2019. For the quarter, the company had adjusted EBITDA income of $53,000. This compares to an adjusted EBITDA loss of $3 million in the second quarter of last year. The increase in adjusted EBITDA in the current period is primarily due to the increased revenue, lower disposable costs from contract manufacturers and decreased personnel expenses due to the cost-cutting initiatives and reorganization completed in 2018.
This concludes our prepared remarks. So, now, we'd like to open the call to your questions. Operator?